Skip to Content
Merck
CN
  • Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis.

Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis.

Antimicrobial agents and chemotherapy (2014-06-04)
Shivani Singh, Andre Kubler, Utpal K Singh, Ajay Singh, Harriet Gardiner, Rajniti Prasad, Paul T Elkington, Jon S Friedland
ABSTRACT

Tuberculosis is characterized by extensive destruction and remodelling of the pulmonary extracellular matrix. Stromal cell-derived matrix metalloproteinases (MMPs) are implicated in this process and may be a target for adjunctive immunotherapy. We hypothesized that MMPs are elevated in bronchoalveolar lavage fluid of tuberculosis patients and that antimycobacterial agents may have a modulatory effect on MMP secretion. Concentrations of MMP-1, -2, -3, -7, -8, and -9 were elevated in the bronchoalveolar lavage fluid from tuberculosis patients compared to those in bronchoalveolar lavage fluid from patients with other pulmonary conditions. There was a positive correlation between MMP-3, MMP-7, and MMP-8 and a chest radiological score of cavitation and parenchymal damage. Respiratory epithelial cell-derived MMP-3 was suppressed by moxifloxacin, rifampicin, and azithromycin in a dose-dependent manner. Respiratory epithelial cell-derived MMP-1 was suppressed by moxifloxacin and azithromycin, whereas MMP-9 secretion was only decreased by moxifloxacin. In contrast, moxifloxacin and azithromycin both increased MMP-1 and -3 secretion from MRC-5 fibroblasts, demonstrating that the effects of these drugs are cell specific. Isoniazid did not affect MMP secretion. In conclusion, MMPs are elevated in bronchoalveolar lavage fluid from tuberculosis patients and correlate with parameters of tissue destruction. Antimycobacterial agents have a hitherto-undescribed immunomodulatory effect on MMP release by stromal cells.

MATERIALS
Product Number
Brand
Product Description

Azithromycin for peak identification, European Pharmacopoeia (EP) Reference Standard
USP
Azithromycin, United States Pharmacopeia (USP) Reference Standard
USP
Levofloxacin, United States Pharmacopeia (USP) Reference Standard
Azithromycin for system suitability, European Pharmacopoeia (EP) Reference Standard
USP
Azithromycin Identity, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Matrix Metalloproteinase-9 human, recombinant, >90% (SDS-PAGE), buffered aqueous solution
Isoniazid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Levofloxacin, 98.0-102.0% anhydrous basis (HPLC)
Supelco
Isoniazid, analytical standard, ≥99% (TLC)
Supelco
Levofloxacin, analytical standard
Supelco
Isoniazid, Vetec, reagent grade, 98%